A kinetic proofreading model for bispecific protein degraders

被引:24
作者
Bartlett, Derek W. [1 ]
Gilbert, Adam M. [2 ]
机构
[1] Pfizer Inc, Pfizer Worldwide Res & Dev, Pharmacokinet Dynam & Metab, San Diego, CA 92121 USA
[2] Pfizer Inc, Pfizer Worldwide Res & Dev, Discovery Sci, Groton, CT 06340 USA
关键词
Mechanistic modeling; Targeted protein degradation; Kinetic proofreading; Translational pharmacology; PROTEOLYSIS-TARGETING CHIMERAS; BINDING-AFFINITY; DEGRADATION; DISCOVERY; CELL; RECOGNITION; DESIGN;
D O I
10.1007/s10928-020-09722-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bispecific protein degraders (BPDs) engage the ubiquitin-proteasome system (UPS) to catalytically degrade intracellular proteins through the formation of ternary complexes with the target protein and E3 ubiquitin ligases. Here, we describe the development of a mechanistic modeling framework for BPDs that includes the reaction network governing ternary complex formation and degradation via the UPS. A critical element of the model framework is a multi-step process that results in a time delay between ternary complex formation and protein degradation, thereby balancing ternary complex stability against UPS degradation rates akin to the kinetic proofreading concept that has been proposed to explain the accuracy and specificity of biological processes including protein translation and T cell receptor signal transduction. Kinetic proofreading likely plays a central role in the cell's ability to regulate substrate recognition and degradation by the UPS, and the model presented here applies this concept in the context of a quantitative pharmacokinetic (PK)-pharmacodynamic (PD) framework to inform the design of potent and selective BPDs.
引用
收藏
页码:149 / 163
页数:15
相关论文
共 31 条
[1]   Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging [J].
Bartlett, DW ;
Davis, ME .
NUCLEIC ACIDS RESEARCH, 2006, 34 (01) :322-333
[2]   Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead [J].
Bondeson, Daniel P. ;
Smith, Blake E. ;
Burslem, George M. ;
Buhimschi, Alexandru D. ;
Hines, John ;
Jaime-Figueroa, Saul ;
Wang, Jing ;
Hamman, Brian D. ;
Ishchenko, Alexey ;
Crews, Craig M. .
CELL CHEMICAL BIOLOGY, 2018, 25 (01) :78-+
[3]  
Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/NCHEMBIO.1858, 10.1038/nchembio.1858]
[4]   Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery [J].
Burslem, George M. ;
Crews, Craig M. .
CELL, 2020, 181 (01) :102-114
[5]   Development of targeted protein degradation therapeutics [J].
Chamberlain, Philip P. ;
Hamann, Lawrence G. .
NATURE CHEMICAL BIOLOGY, 2019, 15 (10) :937-944
[6]  
Chopra Rajesh, 2019, Drug Discov Today Technol, V31, P5, DOI 10.1016/j.ddtec.2019.02.002
[7]   Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones? [J].
Churcher, Ian .
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (02) :444-452
[8]   Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway [J].
Collins, Ian ;
Wang, Hannah ;
Caldwell, John J. ;
Chopra, Raj .
BIOCHEMICAL JOURNAL, 2017, 474 (07) :1127-1147
[9]   A Mathematical Model for the Rational Design of Chimeric Ligands in Selective Drug Therapies [J].
Doldan-Martelli, V. ;
Guantes, R. ;
Miguez, D. G. .
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (02)
[10]   A Comprehensive Mathematical Model for Three-Body Binding Equilibria [J].
Douglass, Eugene F., Jr. ;
Miller, Chad J. ;
Sparer, Gerson ;
Shapiro, Harold ;
Spiegel, David A. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2013, 135 (16) :6092-6099